| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial.
|
Lancet Oncol
|
2012
|
4.19
|
|
2
|
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
|
N Engl J Med
|
2015
|
3.09
|
|
3
|
Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms.
|
Cancer Sci
|
2011
|
1.17
|
|
4
|
Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2009
|
1.13
|
|
5
|
Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing.
|
Brain Tumor Pathol
|
2011
|
1.12
|
|
6
|
Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors.
|
Invest New Drugs
|
2012
|
1.11
|
|
7
|
Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations.
|
Invest New Drugs
|
2014
|
1.03
|
|
8
|
Carcinoma of duodenum arising from Brunner's gland.
|
J Gastroenterol
|
2002
|
1.00
|
|
9
|
Simultaneous identification of 36 mutations in KRAS codons 61 and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit.
|
BMC Cancer
|
2013
|
0.99
|
|
10
|
Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation.
|
Biochem Biophys Res Commun
|
2011
|
0.97
|
|
11
|
S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure.
|
Jpn J Clin Oncol
|
2010
|
0.96
|
|
12
|
Clinical outcome of Japanese metastatic colorectal cancer patients harbouring the KRAS p.G13D mutation treated with cetuximab + irinotecan.
|
Jpn J Clin Oncol
|
2012
|
0.95
|
|
13
|
Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin.
|
Gastric Cancer
|
2010
|
0.95
|
|
14
|
KRAS mutational status in Japanese patients with colorectal cancer: results from a nationwide, multicenter, cross-sectional study.
|
Jpn J Clin Oncol
|
2013
|
0.94
|
|
15
|
Cardiovascular gas on non-traumatic postmortem computed tomography (PMCT): the influence of cardiopulmonary resuscitation.
|
Radiat Med
|
2005
|
0.92
|
|
16
|
Efficacy of sequential methotrexate and 5-fluorouracil (MTX/5FU) in improving oral intake in patients with advanced gastric cancer with severe peritoneal dissemination.
|
Gastric Cancer
|
2009
|
0.91
|
|
17
|
Risk factors and clinical courses of chemoradiation-related arterio-esophageal fistula in esophageal cancer patients with clinical invasion of the aorta.
|
Int J Clin Oncol
|
2011
|
0.91
|
|
18
|
Leptomeningeal carcinomatosis associated with gastric cancer.
|
Int J Clin Oncol
|
2011
|
0.91
|
|
19
|
Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
|
Jpn J Clin Oncol
|
2007
|
0.90
|
|
20
|
Potential effect on cellular response to cadmium of a single-nucleotide A --> G polymorphism in the promoter of the human gene for metallothionein IIA.
|
Hum Genet
|
2006
|
0.89
|
|
21
|
Non-traumatic postmortem computed tomographic (PMCT) findings of the lung.
|
Forensic Sci Int
|
2004
|
0.89
|
|
22
|
Weekly Paclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites: a retrospective study.
|
Jpn J Clin Oncol
|
2010
|
0.89
|
|
23
|
Postmortem computed tomographic (PMCT) demonstration of the relation between gastrointestinal (GI) distension and hepatic portal venous gas (HPVG).
|
Radiat Med
|
2004
|
0.89
|
|
24
|
Postmortem computed tomography for detecting causes of sudden death in infants and children: retrospective review of cases.
|
Radiat Med
|
2006
|
0.89
|
|
25
|
A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer.
|
Invest New Drugs
|
2012
|
0.86
|
|
26
|
Phase I study of sunitinib plus modified FOLFOX6 in Japanese patients with treatment-naive colorectal cancer.
|
Anticancer Res
|
2012
|
0.86
|
|
27
|
Safety, efficacy and pharmacokinetics of neratinib (HKI-272) in Japanese patients with advanced solid tumors: a Phase 1 dose-escalation study.
|
Jpn J Clin Oncol
|
2012
|
0.86
|
|
28
|
Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer.
|
Jpn J Clin Oncol
|
2008
|
0.86
|
|
29
|
Modified FOLFOX-6 therapy for heavily pretreated advanced gastric cancer refractory to fluorouracil, irinotecan, cisplatin and taxanes: a retrospective study.
|
Jpn J Clin Oncol
|
2012
|
0.84
|
|
30
|
Activity of S-1 in advanced or recurrent gastric cancer patients after failure of prior chemotherapy, including irinotecan + cisplatin or fluorouracil (except S-1).
|
Jpn J Clin Oncol
|
2009
|
0.84
|
|
31
|
Comparison of safety and efficacy of S-1 monotherapy and S-1 plus cisplatin therapy in elderly patients with advanced gastric cancer.
|
Int J Clin Oncol
|
2011
|
0.84
|
|
32
|
Dilatation of the heart on postmortem computed tomography (PMCT): comparison with live CT.
|
Radiat Med
|
2003
|
0.84
|
|
33
|
Risk factors of familial pancreatic cancer in Japan: current smoking and recent onset of diabetes.
|
Pancreas
|
2011
|
0.83
|
|
34
|
Irinotecan plus cisplatin therapy and S-1 plus cisplatin therapy for advanced or recurrent gastric cancer in a single institution.
|
Jpn J Clin Oncol
|
2008
|
0.83
|
|
35
|
Safety and efficacy of S-1 monotherapy in elderly patients with advanced gastric cancer.
|
Gastric Cancer
|
2010
|
0.82
|
|
36
|
Nutrition support for head and neck squamous cell carcinoma patients treated with chemoradiotherapy: how often and how long?
|
ISRN Oncol
|
2012
|
0.82
|
|
37
|
Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer.
|
Invest New Drugs
|
2011
|
0.82
|
|
38
|
Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients.
|
Cancer Sci
|
2015
|
0.82
|
|
39
|
Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912.
|
Oncologist
|
2014
|
0.82
|
|
40
|
Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study).
|
Med Oncol
|
2011
|
0.81
|
|
41
|
Postmortem computed tomographic (PMCT) demonstration of fatal hemoptysis by pulmonary tuberculosis--radiological-pathological correlation in a case of rupture of Rasmussen's aneurysm.
|
Radiat Med
|
2004
|
0.81
|
|
42
|
Bacterial species-characteristic profiles of molecular species, and the antigenicity of phospholipids and glycolipids in symbiotic Lactobacillus, Staphylococcus and Streptococcus species.
|
Glycoconj J
|
2012
|
0.79
|
|
43
|
Comparison of combination chemotherapy with irinotecan and cisplatin regimen administered every 2 or 4 weeks in pretreated patients with unresectable or recurrent gastric cancer: retrospective analysis.
|
Int J Clin Oncol
|
2010
|
0.79
|
|
44
|
Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and irinotecan or to fluoropyrimidine, irinotecan and oxaliplatin.
|
Jpn J Clin Oncol
|
2009
|
0.79
|
|
45
|
Postmortem computed tomographic (PMCT) findings of pericardial effusion due to acute aortic dissection.
|
Radiat Med
|
2005
|
0.79
|
|
46
|
A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer.
|
Cancer Chemother Pharmacol
|
2015
|
0.78
|
|
47
|
The specific mitochondrial DNA polymorphism found in Klinefelter's syndrome.
|
Biochem Biophys Res Commun
|
2002
|
0.78
|
|
48
|
Small cell carcinoma of the esophagus responding to fourth-line chemotherapy with weekly paclitaxel.
|
Int J Clin Oncol
|
2005
|
0.78
|
|
49
|
[Targeted therapies for metastatic colorectal cancer].
|
Nihon Rinsho
|
2015
|
0.78
|
|
50
|
Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2014
|
0.78
|
|
51
|
Phase I study of docetaxel, cisplatin and S-1 in patients with advanced gastric cancer.
|
Jpn J Clin Oncol
|
2010
|
0.77
|
|
52
|
Influence of primary tumor resection on survival in asymptomatic patients with incurable stage IV colorectal cancer.
|
Int J Clin Oncol
|
2014
|
0.77
|
|
53
|
Tempo and mode of evolution of the Rh blood group genes before and after gene duplication.
|
Immunogenetics
|
2007
|
0.77
|
|
54
|
Image of the month. A gastric heterotopic pancreas with cystic change.
|
Gastroenterology
|
2005
|
0.77
|
|
55
|
Postmortem magnetic resonance imaging (PMMRI) demonstration of reversible injury phase myocardium in a case of sudden death from acute coronary plaque change.
|
Radiat Med
|
2005
|
0.77
|
|
56
|
First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumours.
|
Invest New Drugs
|
2012
|
0.77
|
|
57
|
Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
|
Invest New Drugs
|
2013
|
0.77
|
|
58
|
Risk Analysis of Pneumonitis in Taxane Therapy After Chemoradiotherapy for Patients With Metastatic or Recurrent Esophageal Cancer.
|
Am J Clin Oncol
|
2015
|
0.76
|
|
59
|
Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy.
|
J Cancer Res Clin Oncol
|
2012
|
0.76
|
|
60
|
Safety of bevacizumab treatment in combination with standard chemotherapy for metastatic colorectal cancer: a retrospective review of 65 Japanese patients.
|
Int J Clin Oncol
|
2009
|
0.76
|
|
61
|
Case of shaken baby syndrome in Japan caused by shaking alone.
|
Pediatr Int
|
2003
|
0.76
|
|
62
|
Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
|
Invest New Drugs
|
2010
|
0.76
|
|
63
|
Endoscopic evaluation of primary tumor response in patients with metastatic colorectal cancer treated by systemic chemotherapy.
|
Int J Clin Oncol
|
2012
|
0.76
|
|
64
|
Estimation of postmortem interval from hypoxic inducible levels of vascular endothelial growth factor.
|
J Forensic Sci
|
2002
|
0.76
|
|
65
|
Postmortem computed tomographic (PMCT) and postmortem magnetic resonance imaging (PMMRI) demonstration of fatal massive retroperitoneal hemorrhage caused by abdominal aortic aneurysm (AAA) rupture.
|
Radiat Med
|
2006
|
0.75
|
|
66
|
Factors that prolong the 'postmortem interval until finding' (PMI-f) among community-dwelling elderly individuals in Japan: analysis of registration data.
|
BMJ Open
|
2012
|
0.75
|
|
67
|
Allele frequencies of a SNP and a 27-bp deletion that are the determinant of earwax type in the ABCC11 gene.
|
Leg Med (Tokyo)
|
2007
|
0.75
|
|
68
|
Tumor KRAS status predicts responsiveness to panitumumab in Japanese patients with metastatic colorectal cancer.
|
Jpn J Clin Oncol
|
2010
|
0.75
|
|
69
|
Presence of beta-linked GalNAc residues on N-glycans of human thyroglobulin.
|
Life Sci
|
2006
|
0.75
|
|
70
|
Origin and evolution of gene for prolactin-induced protein.
|
Gene
|
2006
|
0.75
|
|
71
|
S-1 monotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck after progression on platinum-based chemotherapy.
|
Jpn J Clin Oncol
|
2011
|
0.75
|
|
72
|
[Lower G. I./colon and rectum cancer. III. Current topics concerning postoperative adjuvant chemotherapy].
|
Gan To Kagaku Ryoho
|
2010
|
0.75
|
|
73
|
Sensitivity to previous irinotecan treatment does not predict the efficacy of combination chemotherapy with cetuximab plus irinotecan for wild-type KRAS metastatic colorectal cancer.
|
Eur J Cancer
|
2011
|
0.75
|
|
74
|
Results of a retrospective analysis of gemcitabine as a second-line treatment after chemoradiotherapy and maintenance chemotherapy using 5-fluorouracil in patients with locally advanced pancreatic cancer.
|
J Gastroenterol
|
2008
|
0.75
|
|
75
|
Feasibility of mFOLFOX6 as the adjuvant treatment after curative resection of metastases from colorectal cancer in Japanese patients.
|
Int J Clin Oncol
|
2012
|
0.75
|
|
76
|
[I. Molecular targeted therapy for unresectable wild type K-ras recurrent colon cancer].
|
Gan To Kagaku Ryoho
|
2013
|
0.75
|
|
77
|
[I. Immune Checkpoint Inhibitors in Colorectal Cancer].
|
Gan To Kagaku Ryoho
|
2016
|
0.75
|
|
78
|
[Molecular target therapy and chemotherapy for advanced colorectal cancer].
|
Gan To Kagaku Ryoho
|
2008
|
0.75
|
|
79
|
Serum CA19-9 Response Is an Early Predictive Marker of Efficacy of Regorafenib in Refractory Metastatic Colorectal Cancer.
|
Oncology
|
2017
|
0.75
|